Humira, INN - adalimumab
HUMIRA® (adalimumab) for Rheumatoid Arthritis (RA)
Comparison of effect sizes between the efficacy of treatment with... | Download Scientific Diagram
Higher vs Standard Adalimumab Induction Dosing Regimens and Two Maintenance Strategies: Randomized SERENE CD Trial Results - Gastroenterology
A comparative clinical study of PF-06410293, a candidate adalimumab biosimilar, and adalimumab reference product (Humira®) in the treatment of active rheumatoid arthritis | Arthritis Research & Therapy | Full Text
Clinical, Functional, and Radiographic Benefits of Longterm Adalimumab Plus Methotrexate: Final 10-year Data in Longstanding Rheumatoid Arthritis | The Journal of Rheumatology
Head-to-head comparison of certolizumab pegol versus adalimumab in rheumatoid arthritis: 2-year efficacy and safety results from the randomised EXXELERATE study - The Lancet
HUMIRA (adalimumab) Hidradenitis Suppurativa Clinical Data
HUMIRA (adalimumab), Abbott Laboratories - Package Insert
Bimekizumab versus Adalimumab in Plaque Psoriasis | NEJM
Long-Term Follow-up of Patients With Uveitis Treated With Adalimumab: Response Rates and Reasons for Discontinuation of Therapy - American Journal of Ophthalmology
Comparison of the Efficacy and Safety of Adalimumab (Humira) and the Adalimumab Biosimilar Candidate (HS016) in Chinese Patients with Active Ankylosing Spondylitis: A Multicenter, Randomized, Double-Blind, Parallel, Phase III Clinical Trial
Crohn's Remission and Results With HUMIRA® (adalimumab)
Safety and Efficacy of Adalimumab in Patients with Noninfectious Uveitis in an Ongoing Open-Label Study: VISUAL III - Ophthalmology
Adalimumab Induces and Maintains Clinical Remission in Patients With Moderate-to-Severe Ulcerative Colitis - Gastroenterology
Crohn's Remission and Results With HUMIRA® (adalimumab)
Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis | NEJM
HUMIRA® (adalimumab) for adults with Ulcerative Colitis (UC)
Pre-Clinical Study | Amgevita In Vitro Studies | Amgen
Safety and efficacy of BI 695501 versus adalimumab reference product in patients with advanced Crohn's disease (VOLTAIRE-CD): a multicentre, randomised, double-blind, phase 3 trial - The Lancet Gastroenterology & Hepatology
PDF) A comparative clinical study of PF-06410293, a candidate adalimumab biosimilar, and adalimumab reference product (Humira®) in the treatment of active rheumatoid arthritis
Proactive Monitoring of Adalimumab Trough Concentration Associated With Increased Clinical Remission in Children With Crohn's Disease Compared With Reactive Monitoring - Gastroenterology
Humira 40 mg/0.4 ml Pre-filled Syringe and Pre-filled Pen (Great Britain) - Summary of Product Characteristics (SmPC) - (emc)
Long-Term Safety of Adalimumab (HUMIRA) in Adult Patients from Global Clinical Trials across Multiple Indications: An Updated Analysis in 29,987 Patients Representing 56,951 Patient-Years - ACR Meeting Abstracts
Long-term safety and effectiveness of adalimumab in 462 patients with intestinal Behçet's disease: results from a large real-world observational study
Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial - ScienceDirect
Frontiers | Clinical Evaluation of Humira® Biosimilar ONS-3010 in Healthy Volunteers: Focus on Pharmacokinetics and Pharmacodynamics
